Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTE-162 in CAPS
NCT07247266Phase 1Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Feb 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JTE-162 in cryopyrin-associated periodic syndrome (CAPS), sponsored by Akros Pharma Inc. Primary endpoints: High-sensitivity C-reactive protein at 2 weeks, Serum amyloid A at 2 weeks and 9 more. Started Feb 2026; status: completed.
02
Drugs
JTE-162
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on NCT07247266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247266.